Olympus Corporation

FY guidance revised down (negative) but outlook remains intact (positive): Management revised revenue guidance down ~2% on a constant-currency basis. The main contributor is SIS ship holds / recalls, described as material but largely one-off. However, there were also GI issues (smaller than SIS) and the forecast for GI was revised down as well. Despite this, management reiterated confidence that Q4 growth returns, including in the U.S. (supported by execution changes discussed below).

GI U.S. miss explained as execution/pipeline conversion problem (surprising nuance): On the question “what went wrong in Q3,” management said the issue is not product competitiveness or clinician preference, but commercial execution—specifically that Olympus had a pipeline that wasn’t converted in the U.S. They emphasized tightening pipeline management with greater discipline (e.g., diagnostics, oversight cadence, KPIs). They cited China as an example: after underperformance, they tightened go-to-market focus and pipeline oversight and then saw ~6% growth in Q3 after earlier declines. Expectation: U.S. Q4 growth returns once this conversion discipline is applied.

FDA observations/inspection findings: open matter, proactive remediation ongoing (big risk); costs targeted to SG&A rather than margin reset (mixed): FDA conducted inspections at 8 facilities across the U.S., Europe, and Japan; some resulted in observations. Management stressed: it’s still an open matter while FDA completes evaluation, but Olympus has taken proactive actions, including product holds for patient safety. They reported that about ~70% of impacted products were released, with ~30% still remediating. Importantly, they said the ongoing cost impact should be handled largely within SG&A, while reaffirming ~100+ bps of margin expansion and not resetting the medium-term profitability plan due to these costs.